N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

Werewolf Therapeutics Nasdaqhowl Director Sells 43446 40 in Stock

AnalystRegulationFinancial RegulationTumor

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Insider selling by a director of a small-cap biotech firm; no direct commercial mechanism for any sector. The sale is a personal portfolio move, not a supply/demand or regulatory event. No product, commodity, or supply chain impact.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Director Luke Evnin sold 67,885 shares at $0.64 on May 12, 2026.
  • Evnin sold over 500,000 shares in preceding days.
  • Stock price fell 4.3% to $0.63, market cap $30.72M.
  • Quarterly EPS of ($0.28) beat expectations.

About the publisher

tickerreport.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

tickerreport.com files this story under "analyst" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Werewolf Therapeutics Nasdaqhowl Director Sells 43446 40 in Stock — News Analysis